Charles River to acquire Frontage's bioanalysis and DMPK businesses for about $470 million
FROM THE WIRE · FINANCE.YAHOO.COM
– Strengthens Charles River's Bioanalysis and DMPK Capabilities to Support Clients Across the Drug Development Lifecycle – – Advances Pathway to Purpose Strategy and Enhances Long-Term Growth and Value Creation – WILMINGTON, Mass., November 09, 2026--(BUSINESS WIRE)--Charles…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralMid-sized acquisition strengthening Charles River's drug development services, with limited stock impact.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Charles River will acquire Frontage's bioanalysis and DMPK operations in Exton, Pennsylvania, for about $470 million in cash.
- 02Additional payments of up to $75 million are contingent on future performance of the acquired businesses.
- 03The deal is expected to close in H1 2027, subject to shareholder and regulatory approvals.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets